Vimarsana
Biggest News Aggregation in the World

Timothy Lu News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Timothy Lu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Timothy Lu Today - Breaking & Trending Today

A smart pill to track IBD - Vimarsana News

A smart pill to track IBD

The ingestible device combines engineered bacteria with low-power electronics to monitor gut inflammation in real time.

Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program - Vimarsana News

Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program

– Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1 clinical trial of SENTI-202 expected in 2H...

Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia - Vimarsana News

Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

– First patient in Phase 1 clinical trial expected to be treated in Q2 2024 – – Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 – –...

Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China - Vimarsana News

Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China

– Celest to lead clinical development with technical support from Senti Bio – – First patient expected to be enrolled in China in 1H 2024 – – Senti Bio eligible to receive up to $156 million in milestones and royalties – SOUTH SAN FRANCISCO, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced a new strategic collaborat

Source: yahoo.com
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting - Vimarsana News

Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting

– Two poster presentations highlighting new preclinical data with BlueRock Therapeutics – – Two poster presentations showcasing Senti Bio’s proprietary Gene Circuit platform – SOUTH SAN...